ImmunoPrecise Antibodies Ltd. (IPA)

$4.64

-0.29 (-5.88%)
Rating:
Recommendation:
-
Symbol IPA
Price $4.64
Beta 0.062
Volume Avg. 0.02M
Market Cap 116.848M
Shares () -
52 Week Range 3.51-6.88
1y Target Est -
DCF Unlevered IPA DCF ->
DCF Levered IPA LDCF ->
ROE -38.08% Strong Sell
ROA -28.60% Sell
Operating Margin -
Debt / Equity 20.69% Neutral
P/E -
P/B 2.18 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest IPA news


Healthcare
Biotechnology
NASDAQ Global Market

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.